Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2012; 58(2): 33-38

Pioglitazone, an activator of PPAR-gamma, reduces the expression of kB nuclear factor and inhibits apoptosis in mononuclear cells of peripheral blood in vitro

Kutsenko NL, Vesnina LE, Kaĭdashev IP.

    Research Institute for Genetics and Immunological Groundsof Pathology and Pharmacogenetics, Higher State Educa-tional Establishment of Ukraine “UMSA”, Poltava, Ukraine


In order to examine the impact of PPAR-Y activator on the expression of kB nuclear transcription factor and apoptosis, the peripheral blood mononuclear cells (PBMC) were incu­bated with pioglitazone at concentrations 10, 30 and 100 мM. Expression of NF-kB in CD64+ cells was evaluated by flow cytometry using monoclonal antibodies. The development of apoptosis was evaluated using annexin V and propidium io­dide. Activation of PPAR-Yresulted in a reduction of the number of CD64+ cells and expression of the maximum levels of these receptors. We also obesrved a dose-dependent decrease of NF-kB concentration in PBMC suspension and in CD64+ cells. While analyzing the apoptosis, the reduction of apoptotic cells (reduction of AnV+PI+ cells) has been observed. The re­sults obtained allow to prove that PPAR-Y activation partici­pates in the PBMC apoptosis regulation and in the expression of transcriptional factor NF-kB. Our results indicate for the involvement of PPAR-y in the regulation of NF-kB activity which plays one of the most significant roles in the inflamma­tion realization, oncogenesis, and so on.

Keywords: Peroxisome proliferator-activated receptors-y,pioglitazone, NF-kB nuclear transcription factor, СD64+ cells,apoptosis.


  1. Vinnik I.N., Kaydashev I.P. Clinical characteristics of the effectiveness of pioglitazone in the complex treatment of patients with coronary heart disease with metabolic syndrome . Likar. on right. 2011. N 1 . 2. P. 82-89.
  3. Gromakova I.A., Sorochan P.P., Prokhach N.E., Sukhina O.M., Ponomaryov I.M., Kuzmenko O.V. The transcription factor NF-kB is a meta for the development of radio resistance of the pukhlin . Ukr. rad_ol. journal 2011. N 19. P. 85-89.
  5. Kaydashev I.P., Rasin O.M., Mikityuk M.V. Ator-vastatin and rosiglitazone and induce apoptosis of monocytes . macrophages in blood: the role of polymorphism of the PPAR-Y gene . Likes. 2007. No. 3-4. p. 55-61.
  7. Kuntsevich N.V. The role of the nuclear transcription factor NF-kB in the development of transplant rejection . Tomsk State University Journal. transplantology and the arts. organs. 2010. 12, No. 1. P.72-77.
  9. Lymphocytes: methods: Trans. from English . Ed. J. Klaus. M .: Mir, 1990 . 395 p.
  11. Ao C., Huo Y., Xiong Z. Pioglitazone suppresses the lipopolysaccharide-induced production of inflam­matory factors in mouse macrophages by inactivating NF-kappaB . Cell Biol. Int. 2010. 34 (7). P.723-730. CrossRef PubMed
  13. Ban J.O., Kwak D.H., Oh J.H. Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone . Chem.-Biol. Interact. 2010. 188 (1). P.75-85. CrossRef PubMed
  15. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity . Trends Immunol. 2004. 25. P. 280-288. CrossRef PubMed
  17. de Dios S.T., Frontanilla K.V., Nigro J. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents . J. Diabetes Complications. 2007. N 2. 21. P. 108-117. CrossRef PubMed
  19. Devaraj S., Du Clos T.W., Jialal I. Binding and inter­nalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects . Arteriosclerosis, Thrombosis and Vascular Biology. 2005. 25(7). P. 1359-1363. CrossRef PubMed
  21. Dong C, Davis R.J., Flavell R.A. MAP kinases in the immune response . Annnu. Rev. Immunol. 2002. 20. P.55-72. CrossRef PubMed
  23. Kaidashev I.P., Rasin A.M., Shlykova O.A., Gorbas I.M., Smirnova I.P., Petrushov A.V., Rasin M.S. Fre­quency of Pro12Ala-Polymorphism of the Gene PPARr2 in the Ukrainian Population and Its Possible Relation to the Development of the Metabolic Syn­drome . Cytology and Genetics. 2007. N 5. P. 43-47. CrossRef  
  24. Lawrens T. The nuclear factor NF-kB pathway in in­flammation . Cold Spring Harb. Perspect. Biol. 2009. 1(6). P. 68-73.
  26. Romeo G., Liu W.H., Asnaghi V. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes . Diabetes. 2002. 51. P.2241-2248. CrossRef PubMed
  28. Rossi A., Kapahi P., Natoli G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase . Nature. 2000. 403. P.103-108. CrossRef PubMed
  30. Sasaki M., Jordan P., Welbourne T. Troglitazone, a PPAR-g activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-a . BMC Physiology. 2005. 5. P. 352-359.
  32. Setoguchi K., Misaki Y. , Terauchi Y. , Yamauchi K., Kawahata K., Kadowaki T., Yamamoto K. Peroxisome proliferator-activated receptor-gamma haploinsuffi-ciency enhances B cell proliferative responses and ex­acerbates experimentally induced arthritis . J. Clin. Invest. 2001. 108. P. 1667-1675. CrossRef PubMed PubMedCentral
  34. Sheri M.F., Cleaveland J.S., Grosmaire L.S. A D-aminoacid peptide inhibitor of NF-kB nuclear localization is efficacious in models of inflammatory disease . J. Im­munol. 2000. 2. P. 1004-1012. CrossRef PubMed
  36. Strebel A., Harr T., Bachmann F. Green fluorescent protein as a novel tool to measure apoptosis and ne­crosis . Cytometry. 2001. 43, N 2. P. 126-133. CrossRef  
  37. Valdete Schaub. PPAR-gamma agonists inhibit toll-like receptor mediated activation of dendritic cells via MAP kinase and NF-kappaB pathways . Diss. Des Doct. Der Medicine.-T., 2010. P. 1-50.
  39. Wei-guo Z., Hui Y., Shan L. PPAR-gamma agonists in­hibits Ang II-induced activation of dendritic cells via the MAPK and NF-kappaB pathways . Immunol. Cell Biol. 2010. 88(3). P. 305-312. CrossRef PubMed
  41. Yamamoto Y, Gaynor R.B. Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer . J. Clin. Invest. 2001. 107. P. 135-142. CrossRef PubMed PubMedCentral

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.